Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024
Talphera Inc. (Nasdaq: TLPH), a specialty pharmaceutical company, has announced it will release its second quarter 2024 financial results after market close on Wednesday, August 14, 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talphera Inc. (Nasdaq: TLPH), a specialty pharmaceutical company, has announced it will release its second quarter 2024 financial results after market close on Wednesday, August 14, 2024. The company will host a live webcast and conference call at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide a business update.
Investors can access the webcast through the company's website or join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using the conference ID 28132. The webcast will include a slide presentation, and a replay will be available on Talphera's website for 90 days following the event.
Details
News Market Reaction – TLPH
The recorded move for TLPH in the trading session of this news was -0.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast Information
The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-second-quarter-2024-financial-results-and-corporate-update-call-and-webcast-on-wednesday-august-14-2024-302214600.html
SOURCE Talphera, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.